Extracorporeal Shockwave Therapy in the Treatment of Peyronie's Disease
Uskudar University
50 participants
Jan 10, 2026
INTERVENTIONAL
Conditions
Summary
Investigation of the effectiveness of extracorporeal shock wave therapy in the treatment of Peyronie's disease.
Eligibility
Inclusion Criteria3
- Male individuals aged 18-65 years.
- Having been diagnosed with Peyronie's Disease that has been stable (without increasing pain and curvature) for at least 6 months.
- Presence of palpable penile plaque.
Exclusion Criteria6
- Acute inflammatory stage (painful, progressive)
- Having previously undergone surgery, needle therapy (e.g., Xiaflex), or Extracorporeal Shockwave Therapy for peyronie's disease.
- Uncontrolled diabetes, severe coagulopathy, or receiving anticoagulant therapy.
- History of penile cancer.
- Severe erectile dysfunction.
- Patients who are considered unable to comply with the study protocol or who cannot attend follow-up visits.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Extracorporeal Shockwave Therapy will follow a standard protocol. The treatment is planned as a total of 8 sessions (3000 pulses per session, 2.5 bar pressure, 15 Hz frequency) twice a week using a radial shockwave device. Focusing will be done on the penile shaft via gel according to the plaque localization, and shock waves will be applied to the plaque area.
patients receiving normal routine pharmacological treatment without any special intervention
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07317297